Cargando…

Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty

In head and neck cancer (HNC) there is a need for more personalized treatment based on risk assessment for treatment related adverse events (i.e. toxicities and complications), expected survival and quality of life. Sarcopenia, defined as a condition characterized by loss of skeletal muscle mass and...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bree, Remco, Meerkerk, Christiaan D. A., Halmos, Gyorgy B., Mäkitie, Antti A., Homma, Akihiro, Rodrigo, Juan P., López, Fernando, Takes, Robert P., Vermorken, Jan B., Ferlito, Alfio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150392/
https://www.ncbi.nlm.nih.gov/pubmed/35651790
http://dx.doi.org/10.3389/fonc.2022.884988
_version_ 1784717407359598592
author de Bree, Remco
Meerkerk, Christiaan D. A.
Halmos, Gyorgy B.
Mäkitie, Antti A.
Homma, Akihiro
Rodrigo, Juan P.
López, Fernando
Takes, Robert P.
Vermorken, Jan B.
Ferlito, Alfio
author_facet de Bree, Remco
Meerkerk, Christiaan D. A.
Halmos, Gyorgy B.
Mäkitie, Antti A.
Homma, Akihiro
Rodrigo, Juan P.
López, Fernando
Takes, Robert P.
Vermorken, Jan B.
Ferlito, Alfio
author_sort de Bree, Remco
collection PubMed
description In head and neck cancer (HNC) there is a need for more personalized treatment based on risk assessment for treatment related adverse events (i.e. toxicities and complications), expected survival and quality of life. Sarcopenia, defined as a condition characterized by loss of skeletal muscle mass and function, can predict adverse outcomes in HNC patients. A review of the literature on the measurement of sarcopenia in head and neck cancer patients and its association with frailty was performed. Skeletal muscle mass (SMM) measurement only is often used to determine if sarcopenia is present or not. SMM is most often assessed by measuring skeletal muscle cross-sectional area on CT or MRI at the level of the third lumbar vertebra. As abdominal scans are not always available in HNC patients, measurement of SMM at the third cervical vertebra has been developed and is frequently used. Frailty is often defined as an age-related cumulative decline across multiple physiologic systems, with impaired homeostatic reserve and a reduced capacity of the organism to withstand stress, leading to increased risk of adverse health outcomes. There is no international standard measure of frailty and there are multiple measures of frailty. Both sarcopenia and frailty can predict adverse outcomes and can be used to identify vulnerable patients, select treatment options, adjust treatments, improve patient counselling, improve preoperative nutritional status and anticipate early on complications, length of hospital stay and discharge. Depending on the definitions used for sarcopenia and frailty, there is more or less overlap between both conditions. However, it has yet to be determined if sarcopenia and frailty can be used interchangeably or that they have additional value and should be used in combination to optimize individualized treatment in HNC patients.
format Online
Article
Text
id pubmed-9150392
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91503922022-05-31 Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty de Bree, Remco Meerkerk, Christiaan D. A. Halmos, Gyorgy B. Mäkitie, Antti A. Homma, Akihiro Rodrigo, Juan P. López, Fernando Takes, Robert P. Vermorken, Jan B. Ferlito, Alfio Front Oncol Oncology In head and neck cancer (HNC) there is a need for more personalized treatment based on risk assessment for treatment related adverse events (i.e. toxicities and complications), expected survival and quality of life. Sarcopenia, defined as a condition characterized by loss of skeletal muscle mass and function, can predict adverse outcomes in HNC patients. A review of the literature on the measurement of sarcopenia in head and neck cancer patients and its association with frailty was performed. Skeletal muscle mass (SMM) measurement only is often used to determine if sarcopenia is present or not. SMM is most often assessed by measuring skeletal muscle cross-sectional area on CT or MRI at the level of the third lumbar vertebra. As abdominal scans are not always available in HNC patients, measurement of SMM at the third cervical vertebra has been developed and is frequently used. Frailty is often defined as an age-related cumulative decline across multiple physiologic systems, with impaired homeostatic reserve and a reduced capacity of the organism to withstand stress, leading to increased risk of adverse health outcomes. There is no international standard measure of frailty and there are multiple measures of frailty. Both sarcopenia and frailty can predict adverse outcomes and can be used to identify vulnerable patients, select treatment options, adjust treatments, improve patient counselling, improve preoperative nutritional status and anticipate early on complications, length of hospital stay and discharge. Depending on the definitions used for sarcopenia and frailty, there is more or less overlap between both conditions. However, it has yet to be determined if sarcopenia and frailty can be used interchangeably or that they have additional value and should be used in combination to optimize individualized treatment in HNC patients. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9150392/ /pubmed/35651790 http://dx.doi.org/10.3389/fonc.2022.884988 Text en Copyright © 2022 de Bree, Meerkerk, Halmos, Mäkitie, Homma, Rodrigo, López, Takes, Vermorken and Ferlito https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
de Bree, Remco
Meerkerk, Christiaan D. A.
Halmos, Gyorgy B.
Mäkitie, Antti A.
Homma, Akihiro
Rodrigo, Juan P.
López, Fernando
Takes, Robert P.
Vermorken, Jan B.
Ferlito, Alfio
Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title_full Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title_fullStr Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title_full_unstemmed Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title_short Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty
title_sort measurement of sarcopenia in head and neck cancer patients and its association with frailty
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150392/
https://www.ncbi.nlm.nih.gov/pubmed/35651790
http://dx.doi.org/10.3389/fonc.2022.884988
work_keys_str_mv AT debreeremco measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT meerkerkchristiaanda measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT halmosgyorgyb measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT makitieanttia measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT hommaakihiro measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT rodrigojuanp measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT lopezfernando measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT takesrobertp measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT vermorkenjanb measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty
AT ferlitoalfio measurementofsarcopeniainheadandneckcancerpatientsanditsassociationwithfrailty